Calquence (acalabrutinib) | Friends of Cancer Research

You are here

Calquence (acalabrutinib)

Sponsor: 
AstraZeneca Plc
Indication: 
Monotherapy treatment for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Category: 
Year: 
2019
Date: 
Aug 14th
FDA Status: 
FDA Approval
Approval Date: 
Nov 21st
Approval Year: 
2019